The most common indications for issuing CMV-seronegative products were neonates younger than 4 months (49%, 1228 of 2481),
intrauterine transfusion (23%, 583 of 2481), and HPC or solid organ transplant with CMV-seronegative donor and recipient (14% [345 of 2481] and 13% [316 of 2481], respectively) (Table 2).